A new topical cream with a double-conjugated molecule containing a retinoid and an alpha hydroxy acid (AHA), formulated specifically for patients with blemish-prone skin showed significant improvement in blemishes and pore size and achieve high rates of patient satisfaction, per the outcomes of a study published in Drugs in Dermatology (January 2022).
Related: [Webcast] Understanding Adult Acne
Deanne M. Robinson, MD, FAAD, et al, performed a 12-week study of a new skin care formulation from Skinbetter Science containing the double-conjugated molecule. Twenty subjects with mild/moderate blemish-prone skin used the topical for 12 weeks (19 subjects completed the study).
Their skin was evaluated at four, eight and 12 weeks for skin clarity utilizing the Investigators Global Assessment Scale (0-Clear to 4-Severe) and changes in the appearance of pores using a 6-point scale (0-None to 5-Severe). The researchers also recorded adverse events (AEs) and subject satisfaction scores and performed a secondary analysis of visible, quantitative changes in pores.
The mean percent improvement in skin clarity from baseline was 43% at week four, 48% at week eight and 50% at week 12. Mean percent visible pore improvement from baseline at four, eight and 12 weeks was 33%, 21% and 25%, respectively.
AEs were mild and transient, and by week eight, all subjects reported improvement in overall appearance. The secondary quantitative analysis (n=6) of pores demonstrated an 18% mean improvement in the appearance of pores from baseline to week 12.